Labiotech.eu

News and Trends 17 Oct 2022

Gene activity could help identify risk of kidney cancer spreading

Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet (KI) in Sweden in a preclinical study published in Nature Communications. “This could potentially […]

October 17, 2022 - 4 minutesmins - By Jim Cornall

More News! 17 Oct 2022

Clinical trial of treatment for advanced solid tumors approved

A clinical trial of a drug to treat advanced solid tumors has been approved by the National Medical Products Administration. China-based Akeso Inc., made the announcement on Sunday (October 16) about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific […]

October 17, 2022 - 2 minutesmins - By Liza Laws

In Depth 17 Oct 2022

UK grants that can give biotech startups a vital jump-start

Grants are a vital lifeline that help biotech startups get off the ground, especially for underrepresented entrepreneurs. The Women in Synthetic Biology (WiSB) network recently gave detailed advice for helping U.K. biotech founders access this funding. Women are a big source of talent in the biotech space, both in academic life sciences and in founding […]

October 17, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 17 Oct 2022

Ophthalmology biopharma company Oculis combines with EBAC

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named Oculis Holding SA and will work to accelerate the development […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

Amgen joining Evotec and TIAP to boost Canadian life science companies

Evotec SE and Toronto Innovation Acceleration Partners (TIAP) have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of $14 million to expedite LAB150 programs towards the formation of new companies. LAB150 was created by Evotec and TIAP in 2017 to accelerate Toronto’s […]

October 17, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

Kira Pharmaceuticals gets approval for paroxysmal nocturnal hemoglobinuria study

Kira Pharmaceuticals says the Chinese National Medical Products Administration (NMPA) has cleared the investigational new drug (IND) application for evaluation of KP104. KP104 is a first-in-class bifunctional biologic that selectively targets the alternative and terminal complement pathways, in paroxysmal nocturnal hemoglobinuria (PNH). This approval enables Phase 2 study of the efficacy, safety, tolerability, pharmacokinetics (PK), […]

October 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

Positive results from Milestone Pharmaceuticals’ phase 3 PSVT trial

Milestone Pharmaceuticals Inc. has announced positive topline efficacy and safety data from the phase 3 RAPID clinical trial of etripamil, the company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). “PSVT is an unpredictable, disruptive burden on patients, with current interventions restricted to the costly and inconvenient acute care setting,” said Bruce […]

October 17, 2022 - 4 minutesmins - By Jim Cornall

Caszyme crispr climate change Anastasiia Slynko

Interview 17 Oct 2022

CRISPR gene editing: a key tool for counteracting climate change

Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing technology could fight climate change by boosting agriculture and biodiversity. The invention of CRISPR-Cas gene editing technology in the last decade sparked a revolution in biology, providing researchers a way to make selective and precise changes to an organism’s genetic […]

October 17, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 17 Oct 2022

Clinical Microbiomics acquires MS-Omics

Clinical Microbiomics, a microbiome research company, has acquired MS-Omics, a metabolomics provider based in Denmark. Clinical Microbiomics works on clonal-level microbiome profiling. With the acquisition, Clinical Microbiomics adds expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease. […]

October 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

More positive news announced for Verona’s COPD treatment

Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […]

October 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Way to transform Cas-9 protein into spherical nuclear acid developed

A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […]

October 17, 2022 - 4 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30, a cytokine that may perform immunomodulatory functions, promotes prostate cancer onset and development, but whether it can be a suitable therapeutic target remains to be investigated. In a new study published in the Journal of Hematology & Oncology, researchers at […]

October 17, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gene activity could help identify risk of kidney cancer spreading

Clinical trial of treatment for advanced solid tumors approved

UK grants that can give biotech startups a vital jump-start

Ophthalmology biopharma company Oculis combines with EBAC

Amgen joining Evotec and TIAP to boost Canadian life science companies

Kira Pharmaceuticals gets approval for paroxysmal nocturnal hemoglobinuria study

Positive results from Milestone Pharmaceuticals’ phase 3 PSVT trial

CRISPR gene editing: a key tool for counteracting climate change

Clinical Microbiomics acquires MS-Omics

More positive news announced for Verona’s COPD treatment

Way to transform Cas-9 protein into spherical nuclear acid developed

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!